Author Archives: admin


ingentaconnect Publication: Cell Medicine

Home >> Publication: Cell Medicine

The importance of translating original, peer-reviewed research and review articles on the subject of cell therapy and its application to human diseases to society has led to the formation of the journal Cell Medicine. To ensure high-quality contributions from all areas of transplantation, the same rigorous peer review will be applied to articles published in Cell Medicine. Articles may deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, and stem cells, among others. Basic clinical studies and immunological research papers may also be featured if they have a translational interest. To provide complete coverage of this revolutionary field, Cell Medicine will report on relevant technological advances and their potential for translational medicine. Cell Medicine will be a purely online Open Access journal. There will therefore be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow your work to be disseminated to a wider audience and also entitle you to a free PDF, as well as prepublication of an unedited version of your manuscript.

Publisher: Cognizant Communication Corporation

Read more:
ingentaconnect Publication: Cell Medicine

Janice Dickinson’s Freak Accident and Stem Cell Healing – Us …

Janice Dickinson is on the mend! "On July 7 I had an accident at Rite Aid," Dickinson, 58, tells Us Weekly. "I was walking out of the parking lot and turned to say something to the parking attendant. As soon as I looked back to where I was walking, the bar knocked me out on top of my head."

PHOTOS: Celebrity health scares

The worlds first supermodel headed to a Los Angeles hospital where she underwent a series of tests, leading to a diagnosis of a concussion "with damage to my neck, shoulder blades, back and knee. Ever since then, my life has been miserable," she explained. While Dickinson had the support of her fianc, Dr. Robert "Rocky" Gerner, whom she calls "my right arm" and "my knight in shining armor," she eventually sought treatment in China with longtime friend, Dr. Brian Mehling, founder of Blue Horizon Stem Cells.

PHOTOS: Supermodels: Then and now

Mehling suggested that Dickinson try a stem cell treatment commonly used in China, where stem cells are harvested in a laboratory and then injected into the patients problem area. "In Janice's case," Mehling tells Us about her September procedure, "they injected some stem cells to the spinal fluids so that it could get into the central nervous system and the other half of the cells were injected through an IV in her hand and that would treat the peripheral problem." Dickinson tells Us, "I was back to my normal self instantaneously! I woke up feeing just energized, jazzed to new levels." The outspoken former Americas Next Top Model judge laments that she still cant wear heels 4-and-a-half-months after her accident, and that she will have to have the treatment again, but is still thrilled with the results.

PHOTOS: Memorable reality TV moments

Impressed by the stem cell technology, she also started using and promoting Blue Horizon Special Skin Serum (which does not actually contain stem cells). "This is absolutely the greatest tonic fountain of youth that I've ever found in my life," Dickinson tells Us. The I'm a CelebrityGet Me Out of Here! alum has been using this serum all over her body to improve her skin. "I had all these scars from a gardening accident and all those little scars on my arms and forearms just disappeared! It's spooky!" Mehling and Dickinson are offering Us Weekly readers a $50 discount on their Blue Horizon Special Skim Serum with the code JaniceLovesUs at their website.

Read more:
Janice Dickinson’s Freak Accident and Stem Cell Healing - Us ...

Stem Cell « Medical Research Center

Functions of organism last properly depending on well organized and controlled reproduction, immigration, differentiation and maturation activities unions. It is possible when the cells in organ and tissues are produced regularly. Stem cells are at the top of this system in an organism. Stem cell is that are able to renew themselves by keeping on splitting for long time by remaining same (not differentiated) and they can differentiate according to needs of organism. Stem cells are major source of cell based treatments. Thus some of researches are using human or animal based stem cells from different kind of tissues.

In different kinds of stem cell researches state that mature stem cell have some significant advantage on the cure of damaged tissues. The advantage of using stem cell obtained from an adult is that stem cell can reproduce in patients own cultivation and then before facing regeneration, they can be given to the patient.

Stem cell researches and its treatments are still the very popular topic in the world

STEM CELLS AND WHY ARE THEY IMPORTANT?

Research of stem cell has gained much prominence in recent years for its therapeutic potential in dealing with diseases many of which are essentially incurable by normal therapies. These diseases are characterized by progressive cell loss which has no regenerative potential: e.g. neurodegenerative process leads to Alzheimer and Parkinson diseases. These have become serious health problems as people in advanced societies now live longer. There is great variability in the occurrence and onset of these diseases and the underlying environmental and genetic factors are unknown. The destruction of the beta cells of pancreatic islets is the main cause of diabetes, another serious health problem, can be caused by autoimmune reactions resulting in cell loss (1).

Stem cells are distinct from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity (in G0). Second, under certain physiologic or experimental setting, they can be induced to become tissue or organ specific cells with special functions (2). In some organs, stem cells regularly divide to repair and replace worn out or damaged tissues such as the gut and bone marrow. In other organs, however, such as the heart and the pancreas, stem cells only divide under special conditions. They have the remarkable potential to develop into many different cell types in the body during early life and growth. On the other hand, they serve as a sort of internal repair system in many tissues, dividing essentially without limit to replenish other cells as long as the person or animal is still alive (2).

Scientists frequently worked with two kinds of stem cells from animals and humans: embryonic stem cells and non-embryonic somatic or adult stem cells. Researchers discovered ways to derive embryonic stem cells from early mouse embryos nearly 30 years ago, in 1981. In 1998, the detailed study of the biology of mouse stem cells led to the discovery of a method to derive stem cells from human embryos and grow the cells in the laboratory. These cells are called human embryonic stem cells. They are important for living organisms for many reasons. In the 3- to 5-day-old embryo, called a blastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lung, skin, sperm, eggs and other tissues. In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease (2,3).

In 2006, researchers made another breakthrough by identifying conditions that would allow some specialized adult cells to be reprogrammed genetically to assume a stem cell-like state. This new type of stem cell was called induced pluripotent stem cells (iPSCs) (2).

See the rest here:
Stem Cell « Medical Research Center

KU stem cell center work touted | Kansas Health Institute

KANSAS CITY, Mo. A new non-embryonic stem cell research center at the University of Kansas Medical Center, which stirred legislative controversy when it was authorized earlier this year, has already treated one patient, university officials said Saturday.

Doctors used the patients bone marrow cells as a last-ditch effort to treat a circulatory problem before amputation, said Dr. Buddhadeb Dawn, director of the Midwest Stem Cell Therapy Center. The patient was a man who splits his time between California and Missouri, officials said.

The treatment was part of a clinical study that Dawn said he hoped ultimately would have two dozen participants. He said he did not know the patients condition because of protocols to maintain the objectivity of the study.

The lab opened in July and started producing its own stem cells about a month ago, Dawn said.

Dawn was among about145 people who gathered at the Sheraton Crown Center Hotel here for the stem cell centers inaugural scientific meeting. Others who attended included Dr. Douglas Girod, KU Med executive vice chancellor, and Kansas Gov. Sam Brownback.

This is the beginning, Brownback said, and we are catching it right as the field is really starting to burgeon.

Brownback signed the bill establishing the center in April.

Democrats and moderate Republicans in the Legislature criticized the center as an unfunded mandate for the the university which had not requested. the center. KU officials estimated the center would cost $10.7 million over 10 years.

Girod said university officials have always been excited about the scientific promise of the center, but that they were concerned about the expense while facing state funding cuts.

He said KU Med has received $1.2 million in state funding for the center, with about $700,000 of that going to refurbish existing space in its Cardiovascular Research Institute for the stem cell lab.

See the rest here:
KU stem cell center work touted | Kansas Health Institute

Human Stem Cells Elucidate Mechanisms of Beta-Cell Failure in …

NEW YORK, NY Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute and Columbia University Medical Center (CUMC) have used stem cells created from the skin of patients with a rare form of diabetes to elucidate an important biochemical pathway for beta-cell failure in diabetes. The findings by Linshan Shang and colleagues were published today in Diabetes.

Insulin-producing beta cells produced from skin cells of individuals with a rare form of diabetes, Wolfram syndrome. Credit: Linshan Shang, PhD, the New York Stem Cell Foundation.

Scientists from NYSCF produced induced pluripotent stem (iPS) cells from skin samples from individuals with a rare form of diabetes, Wolfram syndrome. They then derived insulin-producing cells (beta cells) from these iPS cells, creating a human diabetes model in vitro. Next, they showed that the beta cells failed to normally secrete insulin because of protein-foldingor endoplasmic reticulum (ER)stress. They found that a chemical, 4-phenyl butyric acid, that relieves this stress prevents the cells from failing, suggesting a potential target for clinical intervention.

These cells represent an important mechanism that causes beta-cell failure in diabetes. This human iPS-cell model represents a significant step forward in enabling the study of this debilitating disease and the development of new treatments, said Dieter Egli, PhD, principal investigator of the study, senior research fellow at NYSCF, and NYSCFRobertson Stem Cell Investigator.

Wolfram syndrome is a rare, often fatal genetic disorder characterized by the development of insulin-dependent diabetes, vision loss, and deafness. Since all forms of diabetes are ultimately the result of an inability of pancreatic beta cells to provide sufficient insulin in response to blood sugar concentrations, this Wolfram patient stem-cell model enables analysis of a specific pathway leading to beta-cell failure in more prevalent forms of diabetes. It also enables the testing of strategies to restore beta-cell function that may be applicable to all types of diabetes.

Utilizing stem cell technology, we were able to study a devastating condition to better understand what causes the diabetes symptoms, as well as discover possible new drug targets, said Susan L. Solomon, co-founder and chief executive officer of the New York Stem Cell Foundation.

This report highlights again the utility of close examination of rare human disorders as a path to elucidating more common ones, said co-author Rudolph L. Leibel, MD, the Christopher J. Murphy Professor of Diabetes Research and co-director of the Naomi Berrie Diabetes Center at CUMC. Our ability to create functional insulin-producing cells using stem-cell techniques on skin cells from patients with Wolframs syndrome has helped to uncover the role of ER stress in the pathogenesis of diabetes. The use of drugs that reduce such stress may prove useful in the prevention and treatment of diabetes.

Clinicians from the Naomi Berrie Diabetes Center recruited Wolfram syndrome patients to donate a skin sample. All Wolfram patients had childhood-onset diabetes requiring treatment with injected insulin, and all had vision loss. Additional cell lines were obtained from Coriell Institute for Medical Research. The researchers at NYSCF reprogrammed, or reverted, the skin cells to an embryonic-like state to become iPS cells. An iPS cell line generated from a healthy individual was used as a normal control.

The researchers differentiated the iPS cells from the Wolfram subjects and the controls into beta cells, an intricate process that took several weeks. They implanted both Wolfram and control iPS cell-derived beta cells under the kidney capsule of immuno-compromised mice. Beta cells from the Wolfram subjects produced less insulin in the culture dish and secreted less insulin into the bloodstream of the mice when they were challenged with high blood-sugar levels.

A key finding was that these beta cells showed elevated markers of ER stress. Treatment with 4-phenyl butyric acid reduced the ER stress and increased the amount of insulin produced by the beta cells, thereby increasing the ability to secrete insulin in response to glucose.

Visit link:
Human Stem Cells Elucidate Mechanisms of Beta-Cell Failure in ...

Stem cell research | University of Maryland Medical Center

Toggle: English / Spanish

A stem cell is a generic cell that can make exact copies of itself indefinitely. A stem cell has the ability to make specialized cells for various tissues in the body, such as heart muscle, brain tissue, and liver tissue. Stem cells can be saved and usedlater to make specialized cells, when needed.

There are two basic types of stem cells:

Potential uses for stem cells

There are many areas in medicine in which stem cell research could have a significant impact. For example, there are a variety of diseases and injuries in which a patient's cells or tissues are destroyed and must be replaced by tissue or organ transplants. Stem cells may be able to make brand new tissue in these cases, and even cure diseases for which there currently is no good therapy. Diseases that could be helped by stem cells include Alzheimer's and Parkinson's disease, diabetes, spinal cord injury, heart disease, stroke, arthritis, cancer, and burns.

Stem cells could also be used to gain a better understanding of how genetics work in the early stages of cell development. This can help scientists understand why some cells develop abnormally and lead to medical problems such as birth defects and cancer. This might help scientists learn how to prevent some of these diseases.

Finally, stem cells may be useful in the testing and development of drugs. Because stem cells can be used to create unlimited amounts of specialized tissue, such as heart tissue, it may be possible to test how drugs react onsuch tissues before testing the drugs on animals and humans. Drugs could be tested for effectiveness and side effects more rapidly.

Controversy about stem cell research

In August 2001, President George W. Bush approved limited federal funding for stem cell research. While stem cell research has the potential to provide major medical advances, including cures for many diseases, stem cell research is controversial.

The stem cell controversy is based on the belief by opponents that a fertilized egg is fundamentally a human being with rights and interests that need to be protected. Those who oppose stem cell research do not want fetuses and fertilized eggs used for research purposes. However, a team of scientists have developed a technique that was successful in generating mouse stem cells without destroying the mouse embryo. This technique has not yet been attempted on human embryonic tissue. Many other scientists are attempting to create more universally accepted forms of human embryonic stem cells, as well as other types of adult stem cells.

Go here to see the original:
Stem cell research | University of Maryland Medical Center

CellTherapyNews — Cell Therapy News Home

Project A.L.S. Announces Research Effort with Lilly Project A.L.S. announced an agreement with Eli Lilly and Company aimed at helping to accelerate the development of potential therapies for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. [Project A.L.S.] Press Release

Life Stem Genetics Announces Collaborative Agreement with American CryoStem Life Stem Genetics, Inc. announced a strategic collaborative agreement with American CryoStem Corporation (CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries. [Business Wire] Press Release

Actinium Pharmaceuticals Announces Plans for Iomab-B Phase III Pivotal Trial Following Meeting with FDA Actinium Pharmaceuticals, Inc. a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its two most advanced clinical programs. Kaushik J. Dave Ph.D., MBA, President and Chief Executive Officer discussed recent progress and outline development plans for the company's clinical stage products: Iomab-B and Actimab-A. [Actinium Pharmaceuticals, Inc.] Press Release

Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) Alnylam Pharmaceuticals, Inc. announced that it has earned a $7 million milestone from its partner Genzyme, a Sanofi company, for achieving Phase II success with patisiran (ALN-TTR02). [Alnylam Pharmaceuticals] Press Release

ARMO BioSciences Initiates Phase I Clinical Trial of First-in-Class Cancer Immunotherapy ARMO BioSciences, Inc. announced that it initiated the first cohort of patients with advanced solid tumors in a Phase I clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10. [PR Newswire Association LLC] Press Release

Alliqua Receives License to Celgene Cellular Therapeutics Advanced Wound Care ProductsAlliqua, Inc. entered into a licensing agreement with Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation, whereby Alliqua received the right to develop and market the advanced wound care products Biovance and Extracellular Matrix. [Alliqua Inc.] Press Release

Leading Scientists Join BioResearch Open Access Editorial Board under Editor-in-Chief Robert Lanza Dr. Robert Lanza announced that in addition to the distinguished group of Section Editors, including Alan Russell, James Wilson, and Sir Ian Wilmut, among others, fifteen world renowned experts have joined the new Editorial Board of BioResearch Open Access, including ten members of the National Academy of Sciences and Institute of Medicine. [Mary Ann Liebert, Inc.] Press Release

Allergen Research Corporation Announces $17 Million Series A Financing Allergen Research Corporation announced the successful completion of financing to support its upcoming Phase IIb clinical trial to evaluate peanut allergy oral immunotherapy with characterized peanut allergen, as well as related development projects. [Allergen Research Corporation] Press Release

Regeneus to Fast-Track Human Cells under New Japanese Laws The Japanese parliament has passed new laws that provide a rapid approval process specifically designed for human stem cell therapies. Regenerative medicine company, Regeneus, is ready to move on the opportunity. These new laws give the company a unique opportunity to fast-track the clinical trial and potential approval of its new human off-the-shelf cell therapy to treat osteoarthritis and other inflammatory musculoskeletal conditions into the Japanese market. [Regeneus Ltd.] Press Release

New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products Regenerative medicine company Mesoblast Limited gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world's second-largest mature healthcare market. [Mesoblast Limited] Press Release

Go here to read the rest:
CellTherapyNews — Cell Therapy News Home

Bone Marrow Transplantation and Peripheral Blood Stem Cell …

What are bone marrow and hematopoietic stem cells?

Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic or blood-forming stem cells. (Hematopoietic stem cells are different from embryonic stem cells. Embryonic stem cells can develop into every type of cell in the body.) Hematopoietic stem cells divide to form more blood-forming stem cells, or they mature into one of three types of blood cells: white blood cells, which fight infection; red blood cells, which carry oxygen; and platelets, which help the blood to clot. Most hematopoietic stem cells are found in the bone marrow, but some cells, called peripheral blood stem cells (PBSCs), are found in the bloodstream. Blood in the umbilical cord also contains hematopoietic stem cells. Cells from any of these sources can be used in transplants.

What are bone marrow transplantation and peripheral blood stem cell transplantation?

Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:

Why are BMT and PBSCT used in cancer treatment?

One reason BMT and PBSCT are used in cancer treatment is to make it possible for patients to receive very high doses of chemotherapy and/or radiation therapy. To understand more about why BMT and PBSCT are used, it is helpful to understand how chemotherapy and radiation therapy work.

Chemotherapy and radiation therapy generally affect cells that divide rapidly. They are used to treat cancer because cancer cells divide more often than most healthy cells. However, because bone marrow cells also divide frequently, high-dose treatments can severely damage or destroy the patients bone marrow. Without healthy bone marrow, the patient is no longer able to make the blood cells needed to carry oxygen, fight infection, and prevent bleeding. BMT and PBSCT replace stem cells destroyed by treatment. The healthy, transplanted stem cells can restore the bone marrows ability to produce the blood cells the patient needs.

In some types of leukemia, the graft-versus-tumor (GVT) effect that occurs after allogeneic BMT and PBSCT is crucial to the effectiveness of the treatment. GVT occurs when white blood cells from the donor (the graft) identify the cancer cells that remain in the patients body after the chemotherapy and/or radiation therapy (the tumor) as foreign and attack them. (A potential complication of allogeneic transplants called graft-versus-host disease is discussed in Questions 5 and 14.)

What types of cancer are treated with BMT and PBSCT?

BMT and PBSCT are most commonly used in the treatment of leukemia and lymphoma. They are most effective when the leukemia or lymphoma is in remission (the signs and symptoms of cancer have disappeared). BMT and PBSCT are also used to treat other cancers such as neuroblastoma (cancer that arises in immature nerve cells and affects mostly infants and children) and multiple myeloma. Researchers are evaluating BMT and PBSCT in clinical trials (research studies) for the treatment of various types of cancer.

Read the original:
Bone Marrow Transplantation and Peripheral Blood Stem Cell ...

Irvine Stem Cell Treatment Center

The Advancement of Stem Cell Technology

Welcome to the Irvine Stem Cell Treatment Center, and affiliate of the California Stem Cell Treatment Center and the Cell Surgical Network of Beverly Hills and Rancho Mirage, California, USA.

Our affiliated Treatment Centers utilize cutting edge advanced techniques and innovative technology to improve the health and well being of our patients.

At the Irvine Stem Cell Treatment Center, we engage in the investigational use of Adipose Derived Stem Cells (ADSCs) for clinical research and deployment through which patients who are suffering from diseases that may have limited treatment options have an opportunity to respond to stem cell based regenerative treatment and further advance the state of medicine, knowledge, and treatment options for all patients.

Our expertise involves a deep commitment and long-term understanding, knowledge, experience and expertise in clinical research and the advancement of regenerative medicine. Our staff and Physicians at the Irvine Stem Cell Treatment Center have been trained by the Founders and world renown specialists of the California Stem Cell Treatment Center, who have been nationally recognized for working with autologous (your own) adipose derived stem cells providing investigational therapy to patients with various inflammatory and/or degenerative conditions.

Our Centers utilize a fat transfer technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by liposuction on the same day. Using technology developed in South Korea, our Centers have developed an in-office procedure to isolate this cellular medium called the Stromal Vascular Fraction (SVF) which is rich in Stem Cells. Our Founders have also worked in conjunction with a number of international organizations and physicians of great expertise to help develop our protocols for procedures. In 2012, the Cell Surgical Network (CSN) was formed to provide the same high level quality controlled investigational therapy both nationally and internationally.

Our Protocols are approved by an IRB (Institutional Review Board) approved protocol, and accordingly we are able to safely provide adipose (fat)-derived stem cell procedures on an investigational basis to our patients. Modeled after the California Stem Cell Treatment Center, weve formed a multidisciplinary team to evaluate patients with a variety of conditions which are known to often be responsive to Stem Cell therapy.

All affiliate members of the California Stem Cell Treatment Center and the Cell Surgical Network, including our Irvine Stem Cell Treatment Center, contribute to the California Centers IRB approved investigation data. In this manner, we are continuously updating, researching, and learning more on how to help patients and advance the state of the art of regenerative medicine.

All patients who are interested in our investigational treatment protocols will be evaluated by our physicians specially trained in our adipose-derived stem cell procedures and given an honest opinion as to the potential benefits and risks of stem cell therapy for their presenting condition.

The Irvine Stem Cell Treatment Center is proud to be part of the only Institutional Review Board (IRB)-based stem cell treatment network in the United States that utilizes fat-transfer surgical technology. We have an array of ongoing IRB-approved protocols, and we provide care for patients with a wide variety of disorders that may be treated with adult stem cell-based regenerative therapy. At the Irvine Stem Cell Treatment Center we exploit anti-inflammatory, immuno-modulatory and regenerative properties of adult stem cells to mitigate inflammatory and degenerative diseases.

See the article here:
Irvine Stem Cell Treatment Center

Cardiac Stem Cell Therapy How It Works Current Controversies …

What is a hormone? A hormone is one of the many chemical messengers of the body. Hormones are comprised of proteins that form peptide chains and direct the functions of our body. One of the most vital of these chemical messengers is Human Growth Hormone.

We here at Bio-Identical Hormone Replacement Therapy MD, the Conscious Evolution Medical Institute, want to do everything we can to help you make an informed decision about Hormone Replacement Therapy. Therefore, we have compiled this information about the history, benefits, pros, and cons of growth hormone imbalance treatment.

GH (Growth Hormone), also known as STH (somatotropin) is a hormonal protein that stirs growth and also the reproduction of cells in people and many animals. Its a lone chain of one hundred ninety one amino type acids that makes up a hormone of the polypeptide variety. It is manufactured, secreted, and stored by somatotrophic cells inside the lateral wings of the anterior of the pituitary gland.

The following information about the physiology of Growth Hormone also reviews briefly diseases caused by a deficiency of Human Growth Hormone as well as excessive Growth Hormone(gigantism and pituitary acromegaly). It also discusses treatment that features Human Growth Hormone. To learn more about a commonly used growth hormone that is often given to cattle, look up bovine somatotropin.

Terms

Recombinant HGH Human Growth Hormone is called somatotropin as well (In Britain: Somatotrophin)

HGH is an acronym for Human Growth Hormone. This hormone, HGH, is released from or extracted in a measured fashion from the pituitary gland of human beings.

In the 1980s, Human Growth Hormone of biosynthetic form replaced Human Growth Hormone that was derived from the pituitary in bio hormone replacement therapy used in the United States and other locations. Previously, Human Growth Hormone was gathered from processed pituitary glands. derived Biosynthetic HGH, also referred to as Recombinant Human Growth Hormone, is known as Somatropin and the abbreviation rhGH is used.

From the middle of the 1980s, the HGH abbreviation started to carry connotations that were paradoxical. It now quite rarely is used in reference to Human Growth Hormone for the purposes that are indicated.

Go here to see the original:
Cardiac Stem Cell Therapy How It Works Current Controversies ...